Genetic Biomarker Portfolio to Have Important Role in Targeted Drug
Development, Dosing Determination, and Pharmacogenetic Testing
Purchase Expands European Presence, Advances PGxHealth Test
Commercialization and Broadens Geographic Reach of Cogenics'
NEWTON, Mass., Aug. 23 /PRNewswire-FirstCall/ -- Clinical Data, Inc. (Nasdaq: CLDA) announced today that it has acquired privately held Epidauros Biotechnologie AG of Bernried, Germany, in a cash transaction valued at 8.75 million euros (or approximately $11.84 million). Epidauros brings to Clinical Data an established portfolio of proprietary genetic biomarkers, expertise in genetic biomarker discovery, relationships with leading diagnostic companies, and a fast-growing pharmacogenomics services business.
Among the strategic assets acquired by Clinical Data in the transaction is a significant intellectual property portfolio that includes biomarkers in genes relating to prominent drug transporters such as MDR1(1), OCT1(2), MRP1(3), and important cytochrome P450 drug metabolizing genes, such as CYP2B6(4) and CYP2D6(5). MDR1 encodes P-glycoprotein, a key protein involved in drug transport that is known to modulate drug disposition. In addition, the genes CYP2B6, OCT1, and MRP1 are implicated in the absorption, distribution, and metabolism of many drugs that span a variety of therapeutic classes and indications, and are likely to be important in both response and safety profiles for these drugs.
Clinical Data's President and CEO, Drew Fromkin, said, "We are pleased
to have completed this highly strategic transaction, which we believe will
enhance Clinical Data's ability to b
|SOURCE Clinical Data, Inc.|
Copyright©2007 PR Newswire.
All rights reserved